Please use this identifier to cite or link to this item:
http://hdl.handle.net/10637/15073
Emerging Opportunities of Radiotherapy Combined With Immunotherapy in the Era of Breast Cancer Heterogeneity
See/Open:
Emerging_Tsoutsou_et_al_Front_Onco_2018.pdf
Restricted Access
919,66 kB
Adobe PDF
Request a copy
Title: | Emerging Opportunities of Radiotherapy Combined With Immunotherapy in the Era of Breast Cancer Heterogeneity |
Authors : | Tsoutsou, Pelagia G. Zaman, Khalil Martín Lluesma, Silvia Cagnon, Laurene Kandalaft, Lana E. Vozenin, Marie Catherine |
Keywords: | Breast cancer; Subtypes; Immunotherapy; Radiotherapy; TILs |
Publisher: | Frontiers Media |
Citation: | Tsoutsou PG, Zaman K, Martin Lluesma S, Cagnon L, Kandalaft L and Vozenin M-C (2018) Emerging Opportunities of Radiotherapy Combined With Immunotherapy in the Era of Breast Cancer Heterogeneity. Front. Oncol. 8:609. doi: 10.3389/fonc.2018.00609 |
Abstract: | The association of radiotherapy and immunotherapy has recently emerged as an exciting combination that might improve outcomes in many solid tumor settings. In the context of breast cancer, this opportunity is promising and under investigation. Given the heterogeneity of breast cancer, it might be meaningful to study the association of radiotherapy and immunotherapy distinctly among the various breast cancer subtypes. The use of biomarkers, such as tumor infiltrating lymphocytes, which are also associated to breast cancer heterogeneity, might provide an opportunity for tailored studies. This review highlights current knowledge of the association of radiotherapy and immunotherapy in the setting of breast cancer and attempts to highlight the therapeutic opportunities among breast cancer heterogeneity. |
URI: | http://hdl.handle.net/10637/15073 |
Rights : | http://creativecommons.org/licenses/by-nc-nd/4.0/deed.es |
ISSN: | 2234-943X |
Issue Date: | 12-Dec-2018 |
Center : | Universidad San Pablo-CEU |
Appears in Collections: | Medicina |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.